IDiyas

For the Inventor, By the Inventor

Abbott Park, IL, United States of America

Saul A Datwyler

LinkedIn
USPTO Granted Patents = 23 

 

 

Average Co-Inventor Count = 4.7

ph-index = 6

Forward Citations = 66(Granted Patents)


Location History:

  • Evanston, IL (US) (2013 - 2014)
  • Abbott Park, IL (US) (2020 - 2024)

Company Filing History:

goldMedal23 out of 4,177 
 
Abbott Laboratories Corporation
 patents
silverMedal1 out of 596 
 
Cedars-sinai Medical Center
 patents
where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...
Loading Chart...
Loading Chart...
23 patents (USPTO):Explore Patents
1. 12178592 - Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I (2024-12-31),
2. 12163958 - Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1 (2024-12-10),
3. 12123883 - Methods for measuring ubiquitin carboxy—terminal hydrolase L1 levels in blood (2024-10-22),
4. 12105100 - Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 (2024-10-01),
5. 12105098 - Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) (2024-10-01),
6. 12099069 - Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers (2024-09-24),
7. 12092647 - Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers (2024-09-17),
8. 12085567 - Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject (2024-09-10),
9. 11994523 - Biomarkers and methods for diagnosing and evaluating traumatic brain injury (2024-05-28),
10. 11931161 - Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers (2024-03-19),
11. 11169159 - Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood (2021-11-09),
12. 11129564 - Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I (2021-09-28),
13. 11022617 - Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) (2021-06-01),
14. 11016105 - Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 (2021-05-25),
15. 11016092 - Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1 (2021-05-25),

Title: The Innovative Journey of Saul A. Datwyler

Introduction:

Saul A. Datwyler, a pioneering inventor based in Abbott Park, IL (US), has made significant contributions to the field of innovations and patents. His inventive spirit and dedication have led to groundbreaking developments in various industries.

Latest Patents:

Saul A. Datwyler holds several patents in the areas of healthcare technology, pharmaceuticals, and medical devices. His recent patents focus on advanced drug delivery systems and innovative medical treatments that have the potential to revolutionize patient care.

Career Highlights:

Throughout his illustrious career, Saul A. Datwyler has worked with leading research institutions and companies to bring his inventions to life. His expertise in patent law and his deep understanding of the innovation process have been instrumental in his success as an inventor.

Collaborations:

Saul A. Datwyler has collaborated with top universities, pharmaceutical companies, and healthcare providers to develop cutting-edge technologies. His partnerships have resulted in the creation of life-saving medical devices and novel treatment methods that have improved the quality of healthcare worldwide.

Conclusion:

In conclusion, Saul A. Datwyler's passion for innovation and his commitment to excellence have established him as a prominent figure in the world of inventions and patents. His groundbreaking work continues to inspire future generations of inventors and researchers to push the boundaries of what is possible in the realm of technology and healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…